---
sidebar_position: 49
---

# æ–‡ç» 49ï¼šAn MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer

**English Title**: An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer

**ä¸­æ–‡æ¨™é¡Œ**: ç”¨æ–¼å‰åˆ—è…ºç™Œç„¡å‰µè¨ºæ–·å’Œåˆ†ç´šçš„ MRI-ç—…ç†åŸºç¤æ¨¡å‹
**PMID**: 40897909
**æœŸåˆŠ**: Nature cancer
**è©•åˆ†**: 9.0
**æ‡‰ç”¨é ˜åŸŸ**: æ³Œå°¿ç§‘
**DOI**: https://doi.org/10.1038/s43018-025-01041-x

---

## ğŸ“Œ ç¬¬ä¸€å¼µï¼šæ ¸å¿ƒè§€é»å¡

### ä¸»è¦ç™¼ç¾
å¤§è¦æ¨¡å½±åƒ-ç—…ç†é…å°è¨“ç·´

### æ–‡ç»æ‘˜è¦ï¼ˆAbstractï¼‰
Prostate cancer is a leading health concern for men, yet current clinical assessments of tumor aggressiveness rely on invasive procedures that often lead to inconsistencies. There remains a critical need for accurate, noninvasive diagnosis and grading methods. Here we developed a foundation model trained on multiparametric magnetic resonance imaging (MRI) and paired pathology data for noninvasive diagnosis and grading of prostate cancer. Our model, MRI-based Predicted Transformer for Prostate Cancer (MRI-PTPCa), was trained under contrastive learning on nearly 1.3 million image-pathology pairs from over 5,500 patients in discovery, modeling, external and prospective cohorts. During real-world testing, prediction of MRI-PTPCa demonstrated consistency with pathology and superior performance (area under the curve above 0.978; grading accuracy 89.1%) compared with clinical measures and other prediction models. This work introduces a scalable, noninvasive approach to prostate cancer diagnosis and grading, offering a robust tool to support clinical decision-making while reducing reliance on biopsies.

### é—œéµæ•¸æ“š
- **ç ”ç©¶é¡å‹**: æœªåˆ†é¡
- **åœ‹å®¶/åœ°å€**: å¾…æŸ¥
- **ç™¼è¡¨å¹´ä»½**: å¾…æŸ¥
- **ROI æ•¸å€¼**: ç„¡æ•¸å€¼

### æ ¸å¿ƒå‰µæ–°é»
æœ¬ç ”ç©¶çš„ä¸»è¦å‰µæ–°åœ¨æ–¼ï¼šå¤§è¦æ¨¡å½±åƒ-ç—…ç†é…å°è¨“ç·´

---

## âœï¸ ç¬¬äºŒå¼µï¼šParaphrase å¡

### ç ”ç©¶ç›®çš„èˆ‡æ–¹æ³•
æœ¬ç ”ç©¶èšç„¦æ–¼æ³Œå°¿ç§‘é ˜åŸŸï¼Œæ—¨åœ¨æ¢è¨ AI æŠ€è¡“åœ¨é†«ç™‚å ´æ™¯ä¸­çš„æ‡‰ç”¨ã€‚

### ä¸»è¦è²¢ç»
ç ”ç©¶æå‡ºäº†å¤§è¦æ¨¡å½±åƒ-ç—…ç†é…å°è¨“ç·´ï¼Œç‚ºè‡¨åºŠå¯¦è¸æä¾›äº†æ–°çš„è§£æ±ºæ–¹æ¡ˆã€‚

### æŠ€è¡“ç‰¹é»
- æ‡‰ç”¨å ´æ™¯ï¼šæ³Œå°¿ç§‘
- å‰µæ–°ç¨‹åº¦ï¼šè©•åˆ† 9.0/10
- æœŸåˆŠå½±éŸ¿ï¼šç™¼è¡¨æ–¼ Nature cancer

---

## â“ ç¬¬ä¸‰å¼µï¼šå•ç­”å¡

### Q1: é€™é …ç ”ç©¶è§£æ±ºäº†ä»€éº¼å•é¡Œï¼Ÿ
A: æœ¬ç ”ç©¶é‡å°æ³Œå°¿ç§‘é ˜åŸŸçš„æŒ‘æˆ°ï¼Œæå‡ºäº†åŸºæ–¼ AI çš„è§£æ±ºæ–¹æ¡ˆã€‚

### Q2: æ¡ç”¨äº†ä»€éº¼æŠ€è¡“æ–¹æ³•ï¼Ÿ
A: å¤§è¦æ¨¡å½±åƒ-ç—…ç†é…å°è¨“ç·´

### Q3: ç ”ç©¶çš„ä¸»è¦æˆæœæ˜¯ä»€éº¼ï¼Ÿ
A: ç ”ç©¶ç²å¾—äº† 9.0 åˆ†çš„å°ˆå®¶è©•åˆ†ï¼Œè­‰æ˜äº†å…¶åœ¨æ³Œå°¿ç§‘é ˜åŸŸçš„æ‡‰ç”¨åƒ¹å€¼ã€‚

### Q4: æœ‰å“ªäº›å¯¦éš›æ‡‰ç”¨å ´æ™¯ï¼Ÿ
A: ä¸»è¦æ‡‰ç”¨æ–¼æ³Œå°¿ç§‘ï¼Œå¯ç”¨æ–¼æ”¹å–„é†«ç™‚æœå‹™å“è³ªå’Œæ•ˆç‡ã€‚

---

## ğŸ¤” ç¬¬å››å¼µï¼šä¾‹å¤–å¡

### æ½›åœ¨é™åˆ¶
1. **ç ”ç©¶ç¯„åœ**: ç ”ç©¶è©•åˆ†ç‚º 9.0/10ï¼Œå¯èƒ½å­˜åœ¨æ”¹é€²ç©ºé–“
2. **åœ°å€å·®ç•°**: ç ”ç©¶ä¾†è‡ªå¾…æŸ¥ï¼Œå…¶ä»–åœ°å€é©ç”¨æ€§éœ€é©—è­‰
3. **ROI æ•¸æ“š**: ç„¡æ•¸å€¼ï¼Œç¶“æ¿Ÿæ•ˆç›Šè©•ä¼°å¯èƒ½ä¸å®Œæ•´

### éœ€è¦é€²ä¸€æ­¥æ¢è¨çš„å•é¡Œ
1. è©²æŠ€è¡“åœ¨ä¸åŒè¦æ¨¡é†«é™¢çš„é©ç”¨æ€§å¦‚ä½•ï¼Ÿ
2. é•·æœŸä½¿ç”¨çš„æ•ˆæœå’Œç©©å®šæ€§æ˜¯å¦ç¶“éé©—è­‰ï¼Ÿ
3. èˆ‡ç¾æœ‰ç³»çµ±æ•´åˆæ™‚å¯èƒ½é¢è‡¨å“ªäº›æŒ‘æˆ°ï¼Ÿ

### æ‰¹åˆ¤æ€§æ€è€ƒ
- **æŠ€è¡“æˆç†Ÿåº¦**: éœ€è¦è©•ä¼°å¾ç ”ç©¶åˆ°å¯¦éš›éƒ¨ç½²çš„è·é›¢
- **æˆæœ¬æ•ˆç›Š**: ç„¡æ•¸å€¼ï¼Œéœ€è¦æ›´è©³ç´°çš„ç¶“æ¿Ÿåˆ†æ
- **å€«ç†è€ƒé‡**: AI åœ¨æ³Œå°¿ç§‘æ‡‰ç”¨æ™‚çš„å€«ç†å’Œéš±ç§å•é¡Œ
- **å¯æ¨å»£æ€§**: ç ”ç©¶çµæœåœ¨å…¶ä»–é†«ç™‚å ´æ™¯çš„é©ç”¨æ€§

---

## ğŸ“š åƒè€ƒè³‡è¨Š
- **PMID**: [40897909](https://pubmed.ncbi.nlm.nih.gov/40897909/)
- **DOI**: https://doi.org/10.1038/s43018-025-01041-x
- **æœŸåˆŠ**: Nature cancer
